Form 4 for BDTX Black Diamond Therapeutics, Inc.
Accepted 2023-09-18 00:00:00 ET · period of report 2023-09-15 · accession 0001415889-23-013339 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-18 | 2023-09-15 | BDTX | Velleca Mark A. | Pres, CEO, Dir | A - Grant | $3.60 | +5,208 | 46.5K | +13% | +$18.7K |
| D | 2023-09-18 | 2023-09-17 | BDTX | Velleca Mark A. | Pres, CEO, Dir | A - Grant | $0.00 | +1.00M | 1.00M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-15 | A | A | 5,208 | $3.60 | 46,522 | D | — | — | (F2) The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-09-17 | A | A | 1,000,000 | $0.00 | 1,000,000 | D | $3.55 · — to 2033-09-16 | 1,000,000 Common Stock | (F3) 25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter. |